Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does IVERMECTIN Cause Product use in unapproved indication? 366 Reports in FDA Database

Visibly Younger Skin in Weeks

Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.

Discover Synevra

According to the FDA Adverse Event Reporting System (FAERS), 366 reports of Product use in unapproved indication have been filed in association with IVERMECTIN (Ivermectin). This represents 12.1% of all adverse event reports for IVERMECTIN.

366
Reports of Product use in unapproved indication with IVERMECTIN
12.1%
of all IVERMECTIN reports
8
Deaths
38
Hospitalizations

How Dangerous Is Product use in unapproved indication From IVERMECTIN?

Of the 366 reports, 8 (2.2%) resulted in death, 38 (10.4%) required hospitalization, and 3 (0.8%) were considered life-threatening.

Is Product use in unapproved indication Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for IVERMECTIN. However, 366 reports have been filed with the FAERS database.

What Other Side Effects Does IVERMECTIN Cause?

Drug ineffective (538) Off label use (288) Pruritus (217) Erythema (204) Rosacea (131) Skin burning sensation (113) Headache (112) Rash (105) Condition aggravated (89) Skin irritation (82)

What Other Drugs Cause Product use in unapproved indication?

DUPILUMAB (33,452) DICLOFENAC (12,197) METHOTREXATE (8,930) PREDNISONE (7,625) RITUXIMAB (7,519) MYCOPHENOLATE MOFETIL (5,910) ACETAMINOPHEN (5,819) CYCLOPHOSPHAMIDE (5,750) RISPERIDONE (5,551) TACROLIMUS (5,057)

Which IVERMECTIN Alternatives Have Lower Product use in unapproved indication Risk?

IVERMECTIN vs IVOSIDENIB IVERMECTIN vs IXABEPILONE IVERMECTIN vs IXAZOMIB IVERMECTIN vs IXEKIZUMAB IVERMECTIN vs JAKAFI

Related Pages

IVERMECTIN Full Profile All Product use in unapproved indication Reports All Drugs Causing Product use in unapproved indication IVERMECTIN Demographics